ClinicalTrials.gg
Active, not recruitingNCT06213532Updated Nov 9, 2026

CONNECTing to LungCare

An interventional study of Smoking Cessation Intervention and Saliva Collection in Smoking Cessation, Cigarette Smoking-Related Carcinoma and Lung Carcinoma, sponsored by University of California, San Francisco. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Prevention

How we know

Updated Nov 9, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Smoking Cessation by University of California, San Francisco — 5 open to participants now, 6 under way, none of them phase 3. Smoking Cessation · University of California, San Francisco.

Enrollment
32nd of 38
53 · median 174
Started
2024
the only one that year
No phase
31 of 39
5 open now
Registered
34th of 39
by date

Among the 39 studies in Smoking Cessation by University of California, San Francisco, this one is the 32nd largest by enrollment of the 38 interventional ones that give a count, is the only one that started in 2024, is one of 31 with no phase, and was the 34th registered.

Smoking Cessation

1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

5 of the 39 studies in Smoking Cessation by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Smoking Cessation by University of California, San Francisco, or all of them as a file.
02

Study summary

This study evaluates a smoking cessation intervention (CONNECTing to LungCare) for improving shared decision-making conversations about smoking cessation and lung cancer screening between patients and providers. Shared decision making is a patient care model in which providers offer information regarding risks and benefits, patients express their values and preferences, and then healthcare decisions are jointly discussed between the patient and provider. Patient education, aided by decision support tools, can increase patients' knowledge, decrease their decisional conflict, promote decision making, and improve the patients' perception of risk. CONNECTing to LungCare is an interactive education intervention that addresses lung cancer screening and smoking cessation and provides participants with a tailored summary that may make them more likely to have shared decision-making discussions with their providers about smoking cessation and lung cancer screening.

Read the detailed description

PRIMARY OBJECTIVES:

Aim 1: Development of the smoking cessation and LCS intervention, CONNECTing to LungCare.

Aim 2: Test CONNECTing to Lung Care for Feasibility and Acceptability (N=120)

Aim 3: To qualitatively evaluate feasibility and acceptability of the intervention and study procedures from the perspectives of patients, providers, staff and administrators and other stakeholders.

OUTLINE:

BETA TESTING: Participants interact with the CONNECTing to LungCare intervention and provide feedback in support of intervention refinement.

FEASIBILITY TRIAL: Participants are randomized to 1 of 2 groups.

GROUP I: Participants receive the CONNECTing to LungCare intervention, including education about the benefits and risks of LCS and the importance of shared decision making, computerized assessments of the participant's smoking status, readiness to quit and concerns about quitting, and video segments tailored to the participant's responses to assessment questions, prior to their primary care appointment. Participants and their providers receive a tailored summary of the participant's concerns and barriers to quitting to enhance motivation for smoking cessation and shared decision making discussions. Participants then receive up to 3 follow-up phone calls over 10-15 minutes each encouraging them to follow up with their provider, to complete the shared decision-making conversation, obtain LCS if appropriate, and access smoking cessation resources. Participants may also receive brief, tailored follow-up text messages that include links to video segments or cessation resources 1-3 times weekly.

GROUP II: Participants receive usual care from their provider at their primary care appointment.

After completion of study intervention, participants are followed up at 1 and 3 months.

03

Conditions studied

  • Smoking Cessation
  • Cigarette Smoking-Related Carcinoma
  • Lung Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English, Spanish and Cantonese speaking
  • Age >= 18 years old
  • Primary care patients at the University of California, San Francisco (UCSF) General Internal Medicine (GIM) clinics
  • Must be current smokers and/or candidates for Lung Cancer Screening (LCS).

Key Informant Interviews:

- Must be working in one of the clinics participating in CONNECTing to LungCare.

Exclusion criteria

Exclusion Criteria:

  • Not a current smoker
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Other
    Beta testing (CONNECTing to LungCare, feedback)

    Participants interact with the CONNECTing to LungCare intervention and provide feedback in support of intervention refinement.

    Behavioral: Smoking Cessation Intervention · Other: Survey Administration

  • Experimental
    Feasibility trial, Group I (CONNECTing to LungCare)

    Participants receive the CONNECTing to LungCare intervention, including education about the benefits and risks of LCS and the importance of shared decision making, computerized assessments of the participant's smoking status, readiness to quit and concerns about quitting, and video segments tailored to the participant's responses to assessment questions, prior to their primary care appointment. Participants and their providers receive a tailored summary of the participant's concerns and barriers to quitting to enhance motivation for smoking cessation and shared decision-making discussions. Participants then receive up to 3 follow-up phone calls over 10-15 minutes each encouraging them to follow up with their provider, to complete the shared decision-making conversation, obtain LCS if appropriate, and access smoking cessation resources. Participants may also receive brief, tailored follow-up text messages that include links to video segments or cessation resources 1-3 times weekly.

    Behavioral: Smoking Cessation Intervention · Other: Saliva Collection · Other: Survey Administration

  • Active comparator
    Feasibility trial, Group II (usual care)

    Participants receive usual care from their provider at their primary care appointment.

    Behavioral: Smoking Cessation Intervention · Other: Saliva Collection · Other: Survey Administration

Interventions

  • BehavioralSmoking Cessation Intervention

    Multimedia program administered either remotely or in person

    Also known as: CONNECTing to LungCare intervention

  • OtherSaliva Collection

    Saliva samples will be collected from each participant

    Also known as: Biospecimen Collection, Specimen Sample, Saliva Sample

  • OtherSurvey Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Recruitment rate

    The percentage of participants who were contacted and joined the study will be reported.

    Time frame: Up to 1 year

  2. Retention rates

    The percentage of participants who joined the study and completed the program will be reported.

    Time frame: Up to 1 year

  3. Adherence rates

    The percentage of participants who joined the study and completed all tasks within the program will be reported.

    Time frame: Up to 1 year

  4. Overall time required to recruit to the target sample size (Feasibility Cohort)

    The overall time in weeks required to recruit participants for the feasibility cohort will be reported.

    Time frame: Up to 1 year

  5. Number of eligible participants

    The number of eligible participants required to recruit the required sample size will be reported

    Time frame: Up to 1 year

Secondary outcomes

  1. Smoking cessation rates

    Will evaluate the impact of the intervention on smoking cessation rates. Rates of smoking cessation will be measured by self-report and validated by salivary cotinine levels.

    Time frame: At 3 months

  2. Lung cancer screening (LCS) rates

    Rates of LCS will be evaluated through review of the electronic health record (EHR)

    Time frame: Up to 3 months

  3. Shared decision making about LCS

    Evidence of shared decision-making conversation will be obtained through one week follow up phone call and with review of the EHR three months after the primary care physician visit.

    Time frame: Up to 3 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Sep 2027, 33 months after the start.

Of 547 non-industry interventional studies with no phase under Smoking Cessation, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 33 months is above that.

Counting every sponsor, half of 564 studies reached it within 24 months; a quarter within 12 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Nov 2026 → Sep 2027 and completion Nov 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2024
First posted
Jan 19, 2024
StartActual
Dec 3, 2024
Primary completionEst.
Sep 30, 2027was Nov 2026
CompletionEst.
Sep 30, 2027was Nov 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 5, 2026
Primary completion
Nov 30, 2026→Sep 30, 2027
Nov 9, 2026
Study completion
Nov 30, 2026→Sep 30, 2027
Nov 9, 2026
Enrollment
152 (estimated)→53 (actual)
Oct 5, 2026
Show all 2 updates
  1. Nov 9, 2026
    Primary completion Nov 30, 2026→Sep 30, 2027
    Study completion Nov 30, 2026→Sep 30, 2027
    + 1 other change: verification date
  2. Oct 5, 2026
    Recruiting→Active, not recruiting
    Enrollment 152 (estimated)→53 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06213532
Collaborators
Tobacco Related Disease Research Program, Alere San Diego
Responsible party
Sponsor
First posted
Jan 19, 2024
Start date
Dec 3, 2024
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Judith Walsh-Cassidy, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion